Week in Medicine News and Research RSS Feed - Week in Medicine News and Research

Protein expression predicts postop NSCLC recurrence, survival

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer. [More]

Three-gene test may aid earlier lung cancer detection

Methylation of three genes may help with the early diagnosis of non-small-cell lung cancer, research suggests. [More]
Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib. [More]

Amrubicin regimen inferior to irinotecan for extensive SCLC

Irinotecan plus cisplatin remains the gold standard for Japanese patients with extensive small-cell lung cancer, say researchers, after amrubicin plus cisplatin failed to improve survival in their randomised phase III trial. [More]

Solid-dominant lung cancer histology no barrier to segmentectomy

Complete resection with segmentectomy is as effective as lobectomy for patients with solid-dominant clinical stage IA lung adenocarcinoma, Japanese study findings suggest. [More]
Neuropeptide receptors could provide treatment target for chemoresistant SCLC

Neuropeptide receptors could provide treatment target for chemoresistant SCLC

The discovery of a novel broad spectrum neuropeptide antagonist, peptide–1, which is related to the substance P analogue SP-G, could help develop treatments targeted at chemoresistant small-cell lung cancer, indicate study results. [More]

Solid-dominant lung cancer histology no barrier to segmentectomy

Complete resection with segmentectomy is as effective as lobectomy for patients with solid-dominant clinical stage IA lung adenocarcinoma, Japanese study findings suggest. [More]

Lobar offers no survival advantage over sublobar resections in NSCLC

Patients do not survive significantly longer after lobectomy for non-small-cell lung cancer than after wedge resection or segmentectomy, indicate US study results. [More]
Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Noninvasive tumour genotyping using cell-free plasma DNA analysis is feasible, say US researchers who believe the technique will aid patient diagnosis and monitoring. [More]
Lung cancer spread ‘uncommon’ outside of tumour-bearing segment

Lung cancer spread ‘uncommon’ outside of tumour-bearing segment

Lung cancer does not often spread to areas outside of the tumour-bearing segment of the lung when there is no evidence of extrapulmonary nodal metastasis, the tumour is small and peripheral or it has ground glass opacity, study findings show. [More]

15 mm margins cut NSCLC local recurrence risk after wedge resection

Increasing margin distance up to 15 mm significantly decreases the risk of local recurrence among patients undergoing wedge resection for early-stage, non-small-cell lung cancer, US researchers report. [More]

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Genomic fusion testing for echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase genes plus targeted first-line crizotinib is not a cost effective treatment strategy for patients with advanced non-squamous non-small-cell lung cancer, shows a Canadian analysis. [More]

Lymphatic invasion indicates prognosis for lung cancer patients

The presence of lymphatic invasion indicates a worse prognosis for patients with pathologically node-positive lung adenocarcinoma, compared with its absence, indicate Japanese study findings. [More]

Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma cells and subsequently induce their death, according to preclinical study findings. [More]

Hint of survival benefit with bevacizumabpemetrexed maintenance for NSCLC

Updated data from the phase III AVAPERL trial hint that there might be an overall survival benefit of using bevacizumab in combination with pemetrexed as maintenance therapy in patients with advanced nonsmall cell lung cancer. [More]

Plasma microRNA test boosts lung cancer screening

The ability to screen for lung cancer is improved by the development of a plasma 24-microRNA signature classifier, research suggests. [More]

Motesanib boosts carboplatin/paclitaxel efficacy in NSCLC

Adding motesanib to carboplatin/paclitaxel significantly improves overall survival in Asian patients with nonsquamous non-small-cell lung cancer compared with carboplatin/paclitaxel alone, researchers report. [More]

Novel SCLC tumour suppressor gene discovered

Inactivation of the MYC-associated factor X gene, MAX, may play a significant role in the development of small-cell lung cancer, scientists believe. [More]

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Non-small-cell lung cancer patients with very unusual epidermal growth factor receptor mutations may be more likely to be benefit from first-line chemotherapy than a tyrosine kinase inhibitor, research suggests. [More]

Predictors of bone metastasis, skeletal events in lung cancer identified

Researchers have identified a range of factors that are associated with the likelihood that a patient with advanced lung cancer will develop bone metastases or skeletal-related events. [More]